FDA Launches AI Pilot for Real-Time Trial Monitoring

The U.S. Food and Drug Administration announced a pilot program on April 28 to monitor clinical trial data in real time using artificial intelligence and electronic health records, aiming to reduce drug development timelines from the traditional 10 to 12 years. The initiative, unveiled during a press briefing at FDA headquarters in Silver Spring, Maryland, involves direct cloud access to predefined safety and efficacy signals from ongoing trials.

FDA Commissioner Martin Makary described the effort as a challenge to longstanding assumptions in drug development. "For the last 50 years, the medical profession has sadly grown to accept a 10 to 12-year timeframe for new drugs to come to market," Makary said. He noted that about 45 percent of the period between phase 1 trials and regulatory submissions consists of "dead time," during which no active research occurs and staff handle paperwork and other administrative tasks.

The program partners with Paradigm Health, whose AI-powered platform automates data collection and analysis from electronic health records. Regulators can track events such as patient fevers, hospitalizations or tumor shrinkage as they happen, without waiting for...